BioLife Solutions Inc. Common Stock (BLFS)

FairStock Score: 41/100 — MIXED

Key Financials

Strengths

• Generates $6 million in annual free cash flow (0.6% yield on market cap)
• Conservative balance sheet with debt-to-equity of just 0.04, providing financial flexibility
• Altman Z-Score of 17.8 confirms minimal bankruptcy risk and strong solvency
• Healthy net profit margin of 10.9% showing consistent profitability
• Revenue growth of 648.6% demonstrates strong top-line momentum

AI Analysis

BioLife Solutions Inc. Common Stock is a micro-cap healthcare company valued at $1.1 billion. The business generates $102 million in annual revenue with a 10.9% net margin and $6 million in free cash flow. From a quality standpoint, BioLife shows Altman Z-Score of 17.8 confirms fortress-level solvency and negative ROE indicating losses. Growth dynamics show revenue growing at 648.6% and profit growth of -11.2%. Our composite FairStock Score of 41/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

BioLife's 649% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $6 million in annual free cash flow (0.6% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer